Drs. Robinson and Kastelein reply

New England Journal of Medicine

Volumn 373, Issue 8, 2015, Pages 774-

  Robinson, Jennifer G ^a   Kastelein, John J P ^b  

^a UNIVERSITY OF IOWA   (United States)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALIROCUMAB; ATORVASTATIN; CREATINE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ROSUVASTATIN; SIMVASTATIN; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCLONAL ANTIBODY;

ACUTE CORONARY SYNDROME; CARDIOVASCULAR DISEASE; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG SAFETY; EUROPE; EVIDENCE BASED MEDICINE; HIGH RISK POPULATION; HUMAN; LETTER; LOW DRUG DOSE; MUSCLE DISEASE; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; UNITED STATES; BLOOD; CARDIOVASCULAR DISEASES; FEMALE; HYPERCHOLESTEROLEMIA; MALE;

ANTIBODIES, MONOCLONAL; ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE;

EID: 84939857297     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1508222     Document Type: Letter

References (4)

1. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63: 2889-934.
2. Rodriguez F, Olufade T, Heithoff K, Friedman HS, Navaratnam P, Foody JM. Frequency of high-risk patients not receiving high-potency statin (from a large managed care database). Am J Cardiol 2015; 115: 190-5.
3. Halcox JP, Tubach F, Lopez-Garcia E, et al. Low rates of both lipid-lowering therapy use and achievement of low-density lipoprotein cholesterol targets in individuals at high-risk for cardiovascular disease across Europe. PLoS One 2015; 10(2): E0115270.
4. Sanofi/Regeneron. ODYSSEY outcomes: Evaluation of cardiovascular outcomes after an acute coronary syndrome during treatment with alirocumab SAR236553 (REGN727). ClinicalTrials.gov no. NCT01663402. July 2015 (https: //clinicaltrials.gov/ct2/show/ NCT01663402).